However, there is a lack of information on pathogenic variants (PVs) in MMR genes for up to 50–70% of patients with MMR-deficient CRC tumors who were identified in population-based studies (Hampel et al., 2005; Win et al., 2015). This evidence concerns the gene MRC1 and colorectal carcinoma.